{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:48:48Z","timestamp":1783385328336,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12328-022-01593-w","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T05:02:31Z","timestamp":1643000551000},"page":"475-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature"],"prefix":"10.1007","volume":"15","author":[{"given":"Hitomi","family":"Hori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0768-1801","authenticated-orcid":false,"given":"Koichi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Anami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"1593_CR1","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"1593_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134\u201344.","journal-title":"N Engl J Med"},{"key":"1593_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet. 2015;16:257\u2013265.","journal-title":"Lancet"},{"key":"1593_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"1593_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-bind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"1593_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Custem EV, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatelite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11\u20139.","journal-title":"J Clin Oncol"},{"key":"1593_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA, et al. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353.","journal-title":"JAMA Oncol"},{"key":"1593_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","volume":"55","author":"K Mizuno","year":"2020","unstructured":"Mizuno K, Ito T, Ishigami M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastoroenterol. 2020;55:653\u201361.","journal-title":"J Gastoroenterol"},{"key":"1593_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, et al. Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep. 2020;22:39.","journal-title":"Curr Oncol Rep"},{"key":"1593_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529\u201336.","journal-title":"Invest New Drugs"},{"key":"1593_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/hepr.13329","volume":"49","author":"Y Koya","year":"2019","unstructured":"Koya Y, Shibata M, Shinohara N, et al. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab. Hepatol Res. 2019;49:950\u20136.","journal-title":"Hepatol Res"},{"key":"1593_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MD.0000000000025774","volume":"100","author":"Y Hirasawa","year":"2021","unstructured":"Hirasawa Y, Yoshimura K, Matsui H, et al. A case report on severe nibvolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine. 2021;100:23.","journal-title":"Medicine"},{"key":"1593_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.30189","volume":"69","author":"K Ogawa","year":"2019","unstructured":"Ogawa K, Kamimura K, Terai S. Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis. Hepatology. 2019;69:914\u20136.","journal-title":"Hepatology"},{"key":"1593_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:119\u201342.","journal-title":"Ann Oncol"},{"key":"1593_CR15","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"1593_CR16","first-page":"1","volume":"4","author":"K Nakano","year":"2020","unstructured":"Nakano K, Nishizawa M, Fukuda N, et al. Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis. Oxf Med Case Reports. 2020;4:1\u20133.","journal-title":"Oxf Med Case Reports"},{"key":"1593_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61\u20135.","journal-title":"Cancer Immunol Immunother"},{"key":"1593_CR18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2169\/internalmedicine.1981-18","volume":"58","author":"M Kono","year":"2019","unstructured":"Kono M, Sakurai T, Okamoto K, et al. Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis. Intern Med. 2019;58:1263\u20136.","journal-title":"Intern Med"},{"key":"1593_CR19","doi-asserted-by":"publisher","first-page":"E259","DOI":"10.1055\/a-0640-2392","volume":"50","author":"N Kuraoka","year":"2018","unstructured":"Kuraoka N, Hara K, Terai S, et al. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. Endoscopy. 2018;50:E259-261.","journal-title":"Endoscopy"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01593-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-022-01593-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01593-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:43:20Z","timestamp":1659098600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-022-01593-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1007\/s12328-022-01593-w","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"26 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since this is a case report, it did not require ethical approval from our institution\u2019s IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not obtained from the patient in this reported case because he was dead, but formal consent is not required for this type of paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}